• Aker BioMarine posted Q2 2026 net loss of USD 5.4 million, swinging from profit, while net sales rose 5% to USD 57.9 million.
• Operating profit fell to USD 2.9 million; adjusted EBITDA slipped to USD 12.9 million from USD 13.6 million.
• Human Health Ingredients net sales climbed 17% to USD 34.1 million, lifted by higher Superba volumes under a new large US customer contract.
• Consumer Health Products net sales dropped 6% to USD 26.4 million, on lower sales at Lang and Epion.
• Debt was refinanced with a USD 175 million term loan; net interest-bearing debt rose to USD 185.2 million as of June 30.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aker BioMarine ASA published the original content used to generate this news brief on July 10, 2026, and is solely responsible for the information contained therein.